The Boehringer Ingelheim and Lilly Alliance leverages the strengths of two of the world's leading pharmaceutical companies. By joining forces, the companies demonstrate their commitment to people with type 2 diabetes and addressing areas of unmet medical need such as heart failure and chronic kidney disease.